{"organizations": [], "uuid": "255676a3de5aaaffa86a1ffc94d0063fce0e98f7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biohaven-restructures-license-agre/brief-biohaven-restructures-license-agreement-with-bristol-myers-squibb-to-reduce-royalties-payable-on-its-migraine-product-candidates-idUSASC09RP9", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T09:26:00.000+02:00", "replies_count": 0, "uuid": "255676a3de5aaaffa86a1ffc94d0063fce0e98f7"}, "author": "", "url": "https://www.reuters.com/article/brief-biohaven-restructures-license-agre/brief-biohaven-restructures-license-agreement-with-bristol-myers-squibb-to-reduce-royalties-payable-on-its-migraine-product-candidates-idUSASC09RP9", "ord_in_thread": 0, "title": "BRIEF-Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates", "locations": [], "entities": {"persons": [{"name": "biohaven", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "biohaven pharmaceutical holding company ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 7:26 AM / Updated 29 minutes ago BRIEF-Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates Reuters Staff 2 Min Read March 12 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: * BIOHAVEN RESTRUCTURES LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB TO REDUCE ROYALTIES PAYABLE ON ITS MIGRAINE PRODUCT CANDIDATES; TRANSACTION FINANCED THROUGH PRIVATE PLACEMENT WITH LEADING INSTITUTIONAL INVESTORS * BIOHAVEN PHARMACEUTICAL-CO TO PAY BMS UPFRONT PAYMENT OF $50 MILLION IN RETURN FOR LOW SINGLE DIGIT REDUCTION IN ROYALTIES ON NET SALES OF RIMEGEPANT​ * BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍UPFRONT PAYMENT FOR RESTRUCTURING FINANCED THROUGH PRIVATE PLACEMENT OF CO COMMON SHARES TO INVESTORS​ * BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍BIOHAVEN’S OBLIGATIONS TO MAKE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS TO BMS REMAIN UNCHANGED​ * BIOHAVEN PHARMACEUTICAL HOLDING - ‍RESTRUCTURING OF AGREEMENT WITH BRISTOL-MYERS FOR SMALL MOLECULE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PLATFORM​ * BIOHAVEN PHARMACEUTICAL HOLDING CO - CO WILL PAY BMS $50 MILLION IN RETURN FOR A MID-SINGLE DIGIT REDUCTION IN ROYALTIES PAYABLE ON NET SALES OF BHV-3500​ * BIOHAVEN PHARMACEUTICAL-‍RESTRUCTURING WAS FINANCED THROUGH A $55 MILLION PRIVATE PLACEMENT OF 2 MILLION BIOHAVEN COMMON SHARES AT A PRICE OF $27.50 PER SHARE​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T09:26:00.000+02:00", "crawled": "2018-03-12T10:08:24.026+02:00", "highlightTitle": ""}